Financial Tearsheet

Company Overview

Recent Financial News

Date   Headline
Dec 28, 2020 Aytu BioScience Announces Completion of Healight(TM) Safety Study in Critically Ill COVID-19 Patients
Dec 15, 2020 Aytu BioScience Announces Closing of $28.75 Million Bought Deal Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares
Dec 14, 2020 Aytu BioScience to Present at the LD Micro Virtual Investor Conference on Tuesday, December 15 at 2:20pm ET
Dec 10, 2020 Aytu BioScience Increases Previously Announced Bought Deal Offering to $25.0 Million
Dec 10, 2020 Aytu BioScience Announces $10.0 Million Bought Deal Offering

IR Contacts

Hayden IR

James Carbonara
1441 Broadway
Fifth Floor
New York, NY 10018
Office: (646)-755-7412
James@haydenir.com

Stock Performance

Today's Open 7.52
Volume 521,142
Day Range 7.17 - 7.60
52 Week Range 3.35 - 29.90
Bid/Ask 7.42 / 7.44
Bid/Ask Size 700 X 2,500
Previous Close 7.39
Market Cap 128.31 million
Shares Outstanding 17.25 million
Dividend/Yield 0.00 / 0.00%
EPS (TTM) -2.265400
P/E Ratio (TTM) N/A

Recent XBRL Filings

Filing Date Form Type Description View
Nov 12, 2020 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Oct 06, 2020 10-K Annual report htmlhtml   pdfpdf   xbrlxbrl  
May 15, 2020 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Feb 14, 2020 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Nov 14, 2019 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  

Management Team

Josh Disbrow, Chairman & Chief Executive Officer

Jarrett Disbrow, Chief Operating Officer

David Green, Chief Financial Officer

Board of Directors

Josh Disbrow, Chairman & Chief Executive Officer

Gary Cantrell, Director, Chair, Compensation Committee

Carl Dockery, Director, Chair, Nominating & Governance Committee

John Donofrio, Jr., Director, Chair, Audit Committee

Michael Macaluso, Director